Literature DB >> 8157968

Effects of human class I transgenes on Toxoplasma gondii cyst formation.

C R Brown1, C S David, S J Khare, R McLeod.   

Abstract

MHC class I genes are important in the regulation of cyst number in mice perorally infected with Toxoplasma gondii. Since human MHC class I molecules may be capable of functioning as restriction elements in mice, to determine whether class I genes also control outcome of T. gondii infection for humans, a transgenic mouse model was developed using human class I genes in mice. Human HLA-B27 and Cw3 transgenic mice, with the cyst-susceptible B10 mouse background, were tested for resistance to cyst formation after peroral infection with the Me49 strain of T. gondii. Introduction of the B27 gene into susceptible mice made them even more susceptible to T. gondii brain cyst formation. In contrast, HLA-DB27 transgenic mice that have a substitution of the alpha 3 portion of the human class I molecule with the alpha 3 portion of the mouse Kd molecule had the same number of brain cysts as susceptible B10 control mice when perorally infected. Similarly, HLA-Cw3 transgenic mice had the same number of brain cysts as the susceptible B10 controls. These results indicate that the interaction between CD8 on mouse T cells and the human class I molecule in transgenic mice does not always occur, and sometimes may hinder a normal response. Furthermore, B27 and Cw3 transgenes did not generate resistance to cyst formation in infection by T. gondii.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157968

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  The development and biology of bradyzoites of Toxoplasma gondii.

Authors:  L M Weiss; K Kim
Journal:  Front Biosci       Date:  2000-04-01

2.  Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality.

Authors:  J P Dubey; L R Ferreira; J Martins; Rima McLeod
Journal:  Parasitology       Date:  2011-11-14       Impact factor: 3.234

Review 3.  Toxoplasma gondii: 25 years and 25 major advances for the field.

Authors:  John C Boothroyd
Journal:  Int J Parasitol       Date:  2009-07-01       Impact factor: 3.981

4.  Toxoplasma: Immunity and Pathogenesis.

Authors:  Imtiaz A Khan; Charlotte Ouellette; Keer Chen; Magali Moretto
Journal:  Curr Clin Microbiol Rep       Date:  2019-02-04

Review 5.  Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts.

Authors:  J P Dubey; D S Lindsay; C A Speer
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

Review 6.  The CD8 T-cell road to immunotherapy of toxoplasmosis.

Authors:  Rajarshi Bhadra; Jason P Gigley; Imtiaz A Khan
Journal:  Immunotherapy       Date:  2011-06       Impact factor: 4.196

Review 7.  CD8+ T cell immunity in an encephalitis model of Toxoplasma gondii infection.

Authors:  SuJin Hwang; Imtiaz A Khan
Journal:  Semin Immunopathol       Date:  2015-05-06       Impact factor: 9.623

8.  MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes.

Authors:  Erica A Mendes; Bráulia C Caetano; Marcus L O Penido; Oscar Bruna-Romero; Ricardo T Gazzinelli
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

9.  Role of cytokines and major histocompatibility complex restriction in mouse resistance to infection with a natural recombinant strain (type I-III) of Toxoplasma gondii.

Authors:  Blima Fux; Cibele V Rodrigues; Ricardo W Portela; Neide M Silva; Chunlei Su; David Sibley; Ricardo W A Vitor; Ricardo T Gazzinelli
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  CD8 T Cells and Toxoplasma gondii: A New Paradigm.

Authors:  Jason P Gigley; Rajarshi Bhadra; Imtiaz A Khan
Journal:  J Parasitol Res       Date:  2011-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.